2023-08-03 10:19:00
COVID-19 vaccine makers Moderna and Pfizer are hoping conventional distribution and strong demand for their new vaccines targeting the XBB.1.5 variant will make up for the loss that occurred following the Covid-19 pandemic.
Moderna anticipates revenue of $6-8 billion for its Covid-19 vaccines this year, up from a previous forecast of $5 billion, driven by potential demand for 50-100 million doses in the United States. United in autumn.
VOS INDICES
source
The company also plans to sell $2 billion to $4 billion worth of vaccines under commercial contracts in the United States and other countries. However, of the $5 billion expected from government contracts, $1 billion will be carried over to 2024.
Pfizer warned on Tuesday that sales of Covid vaccines were uncertain, adding that this fall’s vaccination rates should serve as a good indicator. Sales of Pfizer’s Covid-19 vaccine fell 83% in the second quarter.
For Moderna, second-quarter Covid-19 vaccine sales fell 94% to $293 million, still above analysts’ average estimate of $233.6 million, data shows. Refinitiv.
With Archyde.com (Leroy Leo in Bangalore and Patrick Wingrove in New York; French version Nathan Vifflin, editing by Kate Entringer)
1691264541
#Moderna #plans #sell #billion #worth #Covid #vaccines
